Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.

Advertisement

Related Content

OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
NSAID Comparative Safety: PRECISION Study, FDA Pertinacity … And Anti-Clotting Agents?
US FDA Taps Pfizer Executive For CDER Deputy Director Slot
CV Trials For Symptomatic Conditions Feasible But Not Always Practical, FDA Panel Says
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
NSAID Panel Could Give Naproxen Labeling Edge
FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
Celebrex Heart Risk To Be Assessed By Cleveland Clinic In Pfizer-Funded Study
Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel